大江基因 (6879.TW) 2025Q2 shows a significant decrease in contract liabilities year-on-year (below -10%). This suggests a notable slowdown in new orders, downward trends in market demand or product competitiveness, and potential pressure on future revenue and profitability. Investors are advised to closely monitor the company’s ability to secure new contracts and watch for industry downturn risks.